ASX:BXN Bioxyne (BXN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bioxyne Stock (ASX:BXN) 30 days 90 days 365 days Advanced Chart Get Bioxyne alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume174,489 shsAverage VolumeN/AMarket CapitalizationA$96.31 millionP/E RatioN/ADividend Yield2.51%Price TargetN/AConsensus RatingN/A Company Overview Bioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. The company also provides product research and development services, and telemedicine services. In addition, it operates BLS Clinics, a telehealth platform. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia. Read More Receive BXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxyne and its competitors with MarketBeat's FREE daily newsletter. Email Address BXN Stock News HeadlinesBioxyne Limited Releases Business Update and Progress ReportJune 19, 2025 | tipranks.comBioxyne Limited Expands into German Cannabis Market with €3.2 Million AgreementJune 17, 2025 | tipranks.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 5 at 2:00 AM | Brownstone Research (Ad)Bioxyne Limited Strengthens Advisory Board with Cannabis ExpertApril 2, 2025 | tipranks.comBioxyne Secures $7M Exclusive Manufacturing Deal with NectarTekApril 2, 2025 | tipranks.comBioxyne Limited Achieves Record Q2 Results, Plans Expansion into EuropeJanuary 27, 2025 | tipranks.comBioxyne Limited Announces Cessation of SecuritiesDecember 19, 2024 | tipranks.comBioxyne Limited Director’s Interest UpdateDecember 19, 2024 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorConsumer Defensive Industry Packaged Foods Sub-IndustryN/A Current SymbolASX:BXN CIKN/A Webwww.bioxyne.com Phone61 2 9078 8180FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$12.80 million Net Margins-142.90% Pretax MarginN/A Return on Equity-409.92% Return on Assets-5.80% Debt Debt-to-Equity Ratio18.68 Current Ratio1.92 Quick Ratio2.30 Sales & Book Value Annual SalesA$9.64 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.75 Book ValueA$0.00 per share Price / BookN/AMiscellaneous Outstanding Shares2,050,000,000Free FloatN/AMarket CapA$96.31 million OptionableNot Optionable Beta0.78 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (ASX:BXN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxyne Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxyne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
